Clinical Trial

BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01)

Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The objective of the study is to evaluate the efficacy and safety of BL-M14D1 in combination with Atezolizumab compared to Standard-of-Care Therapy in adult participants with previously untreated extensive-stage small cell lung cancer (ES-SCLC).
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-05-28.
Trial Details
NCT Number NCT07625644
Lead Sponsor SystImmune Inc.
Conditions Small Cell Lung Cancer Extensive Stage, Small-cell Lung Cancer, Small Cell Carcinoma, Sclc, SCLC,Extensive Stage, Lung Cancer, Lung Cancer Metastatic, Lung Cancer Stage IV
Enrollment 550 participants
Start Date 2026-06
Primary Completion 2030-01 (estimated)
Study Completion 2031-06 (estimated)
Updated on ClinicalTrials.gov 2026-07-16